Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Eli Lilly stories

Nov 16, 2026

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.

Nov 16, 2026·3 sources
00

Eli Lilly acquires Calytrix Bio for up to $1.5B in rare blood cancer push

Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to expand development of treatments for rare blood cancers known as myeloproliferative neoplasms, its 14th or 15th acquisition of 2026.

Nov 16, 2026·3 sources
00
Nov 15, 2026

Oyster Therapeutics raises $60M for brain-penetrating small molecule degraders

Brain-focused startup Oyster Therapeutics secured $60 million to advance its lead program targeting pathological tau in Alzheimer's disease, with Eli Lilly participating in the round.

Nov 15, 2026·3 sources
00
Nov 14, 2026

Eli Lilly releases new obesity drug clinical trial data at ObesityWeek

Eli Lilly released new clinical trial data for its obesity drugs at the ObesityWeek 2026 medical conference, showing weight loss benefits, though full results have not yet been published.

Nov 14, 2026·2 sources
00
Nov 12, 2026

FDA quietly shelves Trump's drug fast-track voucher program amid agency chaos

No new drugs have received a voucher under the FDA's fast-track review program since Marty Makary left the agency in May, with internal documents and sources indicating the program has been effectively abandoned amid ongoing agency turmoil.

Nov 12, 2026·2 sources
00
Nov 9, 2026

FDA requires GLP-1 drugmakers to add warning for rare eye condition

The FDA ordered makers of all GLP-1 medications, including Ozempic and Zepbound, to add label warnings about nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause permanent vision loss.

Nov 9, 2026·8 sources
00
Nov 7, 2026

T-Therapeutics raises $133M Series B for T-cell therapies in cancer and autoimmune disease

UK-based T-Therapeutics closed a $133 million Series B funding round led by Advent Life Sciences and British Business Bank to advance T-cell therapies targeting cancer and autoimmune diseases.

Nov 7, 2026·2 sources
00
Nov 6, 2026

Eli Lilly strikes deal to sell obesity drugs directly on Hims & Hers platform

Eli Lilly announced a partnership allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform, sending Hims & Hers shares up more than 7%. The deal marks a significant course change for Hims, which had previously sold compounded GLP-1 knockoffs.

Nov 6, 2026·3 sources
00
Nov 5, 2026

T-Therapeutics raises $133M Series B for cancer and autoimmune T cell receptor drugs

UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.

Nov 5, 2026·2 sources
00
Nov 4, 2026

AstraZeneca made $10 billion offer for obesity drugmaker Rhythm Pharmaceuticals

AstraZeneca made a $10 billion takeover offer for Rhythm Pharmaceuticals, which specializes in treatments for metabolic conditions and severe obesity, according to sources familiar with the matter.

Nov 4, 2026·2 sources
00

Novo Nordisk raises 2026 outlook for third time on strong Wegovy pill sales

Novo Nordisk raised its full-year forecast for the third time in 2026 after third-quarter sales of its Wegovy weight-loss pill reached $807 million, beating analyst expectations and driving stronger-than-expected quarterly earnings.

Nov 4, 2026·4 sources
00
Nov 3, 2026

Ultragenyx to cut 20% of workforce after Wilson disease gene therapy failure

Ultragenyx Therapeutics announced plans to lay off approximately 20% of its employees and discontinue development of its Wilson disease gene therapy GTX-102 following a major setback in Angelman syndrome trials.

Nov 3, 2026·2 sources
00

Pfizer raises 2026 outlook on strong demand for non-Covid drugs

Pfizer raised its full-year profit and revenue outlook after third-quarter results beat estimates, driven by growing demand for newly launched and acquired medicines as Covid product sales decline.

Nov 3, 2026·4 sources
00
Nov 2, 2026

Novartis heart drug failure raises questions about genetic cholesterol target

The recent failure of a Novartis experimental heart drug in a large trial has raised questions among cardiologists about the widely held idea that reducing levels of genetically set cholesterol improves cardiovascular outcomes.

Nov 2, 2026·2 sources
00
Oct 29, 2026

Eli Lilly raises revenue forecast on weight-loss drug demand

Eli Lilly raised its full-year revenue forecast by $5 billion and beat third-quarter profit estimates driven by booming demand for its injectable weight-loss drugs, particularly among older Americans.

Oct 29, 2026·2 sources
00
Oct 28, 2026

Eli Lilly's retatrutide outperforms Ozempic in head-to-head diabetes trial

Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.

Oct 28, 2026·3 sources
00
Oct 26, 2026

Eli Lilly wins court ruling allowing weight-loss drug ads against Novo Nordisk

A US court denied Novo Nordisk's request to temporarily block Eli Lilly from using advertisements claiming its obesity drugs are more powerful, a setback for Novo as it battles to regain market share.

Oct 26, 2026·2 sources
00
Oct 19, 2026

Mirikizumab achieves clinical remission in pediatric ulcerative colitis phase 3 trial

Eli Lilly's mirikizumab (Omvoh) achieved clinical and endoscopic remission rates in children with ulcerative colitis that exceeded historical adult placebo outcomes at week 12 in the SHINE-2 phase 3 study. The positive pediatric data could provide a competitive advantage for the IL-23p19 inhibitor in the inflammatory bowel disease market.

Oct 19, 2026·3 sources
00
Oct 16, 2026

Eli Lilly's weight-loss pill Foundayo wins EU regulatory backing

The European Medicines Agency's committee recommended approval of Eli Lilly's oral weight-loss drug Foundayo for obesity and diabetes, following Novo Nordisk's Wegovy as the second oral obesity drug to win the agency's backing.

Oct 16, 2026·2 sources
00
Oct 7, 2026

Zealand Pharma and Roche's amylin drug achieves 9.2% weight loss in Phase 2 trial

Zealand Pharma and Roche reported that their experimental amylin drug helped patients with type 2 diabetes lose up to 9.2% of body weight in a mid-stage trial, as they seek to compete with Eli Lilly in the obesity and diabetes market.

Oct 7, 2026·2 sources
00
Oct 5, 2026

FDA approves Lilly's Jaypirca as first-line CLL therapy

The FDA approved pirtobrutinib (Jaypirca, Eli Lilly) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.

Oct 5, 2026·2 sources
00
Sep 30, 2026

Eli Lilly's amylin-Zepbound combination shows record 23% weight loss in diabetes trial

Eli Lilly reported that its experimental combination of amylin drug eloraTZP with Zepbound (tirzepatide) achieved up to 23% weight loss in patients with type 2 diabetes and obesity, outperforming Zepbound alone and representing the highest weight loss seen in similar studies to date.

Sep 30, 2026·6 sources
00
Sep 29, 2026

Eli Lilly's retatrutide helps diabetes patients lose up to 21% body weight in late-stage trial

Eli Lilly reported that its experimental triple-agonist drug retatrutide helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial, with more than half of patients dropping below the obesity threshold.

Sep 29, 2026·3 sources
00
Sep 17, 2026

Novo Nordisk signs up to $1.4B partnership with Orbis Medicines for cardiometabolic drugs

Novo Nordisk agreed to a partnership worth up to $1.4 billion with Lilly-backed Orbis Medicines to develop macrocycle pills for heart and metabolic diseases, marking Orbis' first major pharma deal.

Sep 17, 2026·2 sources
00
Aug 24, 2026

FDA clears Roche and Eli Lilly's blood test for Alzheimer's disease detection

The FDA has cleared a blood test developed by Roche and Eli Lilly to help identify signs of Alzheimer's disease in people aged 55 and older with cognitive decline.

Aug 24, 2026·3 sources
00
Aug 12, 2026

Eli Lilly escalates legal fight against black market for experimental weight-loss drug retatrutide

Eli Lilly is stepping up legal action against a booming black market for retatrutide, an experimental weight-loss drug the company is counting on to expand its franchise beyond approved medications like Zepbound.

Aug 12, 2026·2 sources
00
Jul 23, 2026

Eli Lilly's retatrutide shows positive Phase 3 results, plans Q1 2027 FDA application

Eli Lilly announced positive results from two additional Phase 3 trials of its experimental obesity drug retatrutide (a 'triple-G' GLP-1 receptor agonist), showing it did not increase overall heart risk. The company plans to submit an FDA application in Q1 2027.

Jul 23, 2026·3 sources
00
Jul 15, 2026

Eli Lilly nears deal to acquire psychedelic drugmaker AtaiBeckley

Eli Lilly is in advanced talks to acquire AtaiBeckley, a psychedelic medicine company, with a deal potentially announced this week. The acquisition underscores growing interest from major pharmaceutical companies in psychedelic therapies.

Jul 15, 2026·2 sources
00
Jul 14, 2026

Study finds frailty risks with GLP-1 drugs in older adults

A large study found potential signs of frailty in older adults taking Eli Lilly's Zepbound may signal relatively high risks for adverse outcomes, raising concerns about GLP-1 obesity drug use in elderly populations.

Jul 14, 2026·1 source
00
Jun 29, 2026

FDA Selects Eli Lilly and Regeneron for Pilot Program to Accelerate Manufacturing Facility Reviews

The FDA selected seven companies including Eli Lilly and Regeneron for a pilot program designed to speed up reviews of new domestic pharmaceutical manufacturing facilities, aiming to strengthen U.S. drug supply chains.

Jun 29, 2026·2 sources
00
Jun 23, 2026

Eli Lilly Grants Compassionate Use Access to Experimental Obesity Drug Retatrutide for Single Patient

Eli Lilly provided its experimental 'triple-G' weight loss drug retatrutide to a 79-year-old patient through the FDA's compassionate use program, marking an extremely rare instance of pre-approval access to an obesity medication.

Jun 23, 2026·2 sources
00
May 28, 2026

CVS Health Restores Coverage of Eli Lilly's Zepbound and Adds New Obesity Pill to Drug Plans

CVS Health announced it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option and begin coverage for the drugmaker's newly approved obesity pill, Forza.

May 28, 2026·2 sources
00
May 26, 2026

Eli Lilly Acquires Three Vaccine Developers, Expanding Infectious Disease Portfolio

Eli Lilly is acquiring three small vaccine developers, marking a significant expansion into infectious disease vaccines and providing a boost to the vaccine development field.

May 26, 2026·1 source
00
May 25, 2026

Eli Lilly's Gene-Editing Therapy Reduces Cholesterol by 62% in Early Clinical Trial

Eli Lilly reported that a high dose of its gene-editing therapy from Verve Therapeutics reduced cholesterol levels by 62% in participants in an early-stage clinical trial, representing a significant advance in gene-editing treatments for cardiovascular disease.

May 25, 2026·1 source
00
May 18, 2026

Trump Invested in Eli Lilly Stock as Administration Boosted Obesity Drug Policies

New ethics disclosures reveal President Trump purchased stock in Eli Lilly and an injectable device manufacturer while his health agencies implemented policies benefiting these companies' obesity drug products.

May 18, 2026·1 source
00
May 5, 2026

French Regulator Fines Novo Nordisk and Eli Lilly Over Weight Loss Drug Ad Campaigns

France's medicines regulator has imposed fines on Novo Nordisk and Eli Lilly for their weight loss drug advertising campaigns, marking a significant regulatory action against the pharmaceutical giants' marketing practices.

May 5, 2026·1 source
00
May 3, 2026

Eli Lilly Raises 2026 Guidance as GLP-1 Drug Demand Surges in Q1

Eli Lilly reported strong Q1 2026 financial results driven by massive growth in Mounjaro and Zepbound sales, leading the company to raise its full-year guidance amid surging demand for GLP-1 medications.

May 3, 2026·1 source
00
May 1, 2026

FDA Moves to Remove GLP-1 Weight Loss Drugs from Compounding List

FDA announced plans to exclude semaglutide, tirzepatide, and liraglutide from its 503B compounding list, citing no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.

May 1, 2026·1 source
00
Apr 28, 2026

Eli Lilly Partners with AI Startup Profluent to Develop Next-Generation Gene Editors Beyond CRISPR

Eli Lilly has entered a deal with AI startup Profluent to develop AI-designed enzymes capable of inserting entire genes, moving beyond traditional CRISPR technology. The partnership aims to reshape genetic medicine by using artificial intelligence to create novel gene editing tools.

Apr 28, 2026·1 source
00
Apr 16, 2026

FDA Requests Additional Liver Injury Data on Eli Lilly Obesity Pill Foundayo

The FDA has asked Eli Lilly for more data on liver injury linked to its newly approved obesity pill Foundayo.

Apr 16, 2026·1 source
00

Top claims

  • ▪Almost 80 percent of children aged 6 to under 12 given Wegovy in Novo Nordisk's trial reduced their body mass index by at least 10 percent over 68 weeks
  • ▪In the 68-week trial, 40 percent of children aged 6 to under 12 taking Wegovy were no longer classified as having obesity, compared with none in the placebo group
  • ▪As of November 16, 2026, Novo Nordisk has not announced if or when it will file for regulatory approval to treat children under 12 with Wegovy

People involved

Vinay PrasadDonald Trump

Subtopics

Drug Policy, Pricing & Approval16Pharma15Novo Nordisk14Zepbound13Clinical trials10GLP-1 medications10Obesity treatment10Pharmaceutical Industry10Weight management10Lifestyle, Wellness and Nutrition9Weight loss medications & GLP-1 drugs9Drug Approval and Clinical Trials8Weight loss drugs8Retatrutide7Drug development6Biotech startup4GLP-1 / Weight-Loss Medications4Autoimmune disease treatments3Cancer & Oncology3Drug safety3Foundao3GLP-1 receptor agonists3Healthcare Policy3Pharmaceutical earnings3

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories